免疫治疗能与靶向药物联合使用吗？

2020-01-09

7485 0

作者: 健康全记录

既往多项研究显示，对于携带EGFR或ALK突变的NSCLC患者，PD-1/PD-L1抑制剂的有效率只有3%～7%【1】，远不如靶向治疗，而如果将靶向治疗与PD-1/PD-L1抑制剂联合，免疫相关性肺炎的发生率高（TATTON和CAURAL研究均因此提前终止）【2,3】。因此，目前证据不支持PD-1/PD-L1抑制剂联合靶向治疗。

参考文献

[1] Gainor JF, et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1. Pathway Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2016;22:4585-4593.

[2] NIH. AZD9291 in Combination With Ascending Doses of Novel Therapeutics （TATTON）; [accessed 2018 May 21]; Available from: https://clinicaltrials.gov/ct2/show/NCT02143466.

[3] NIH. Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL); [accessed 2018 May 21]; Available from: https://clinicaltrials.gov/ct2/show/NCT02454933.